Skip to main content

Cosmos Health Inc.

COSM
Exchange
Nasdaq
Industry
Wholesale-Drugs, Proprietaries & Druggists' Sundries
SEC CIK
0001474167

No open-market purchases or sales by Cosmos Health Inc. insiders were filed in the last 90 days; 30 institutions reported holding it in 13F filings for Q3 2026, worth $3.20M in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 1:15 PM ET

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Net loss for FY2025: $19.1M (29.3% of revenue).

Income statement

Each column is one fiscal year, newest first.

Income statement of Cosmos Health Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K/A
Reported–––––
Revenue$65.3M$54.4M$53.4M$50.3M$56.2M
Cost of revenue$57.4M$50.1M$49.0M$44.4M$47.9M
Gross profit$7.90M$4.31M$4.35M$5.96M$8.33M
Operating expenses$24.6M$19.9M$26.2M$13.4M$12.9M
Research and development$519.4K$533.3K–––
Selling, general and administrative$15.6M$11.7M$19.6M$10.2M$9.21M
Operating income-$16.7M-$15.5M-$21.8M-$7.47M-$4.53M
Interest expense$1.90M$1.01M$866.5K$2.35M$2.82M
Income tax$0$0–$775.1K-$114.0K
Net income-$19.1M-$16.2M-$18.5M-$13.8M-$7.96M
EPS, basic$-0.63$-1.17$-2.15$-33.16$-0.95
EPS, diluted$-0.63$-1.17$-2.15$-33.16$-0.95
Weighted shares, basic30.3M19.1M12.0M1.93M16.4M
Weighted shares, diluted30.3M––1.93M16.4M
Margins and growth
Gross margin12.1%7.9%8.1%11.8%14.8%
Operating margin-25.6%-28.6%-40.9%-14.8%-8.1%
Net margin-29.3%-29.7%-34.7%-27.5%-14.2%
Revenue growth, year over year+19.9%+2.0%+6.0%−10.5%+1.5%
Net income growth, year over year––––−1,070.0%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Cosmos Health Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K/A
Reported–––––
Cash and equivalents$715.7K––$20.7M$286.5K
Short-term investments$46.2K$21.1K$20.1K$14.9K$6.70K
Accounts receivable$19.6M$13.5M$19.8M––
Inventory$5.78M$4.36M$4.79M$3.45M$3.15M
Total current assets$38.4M$25.5M$36.6M$56.0M$40.9M
Property, plant and equipment$10.6M$9.69M$10.5M$1.82M$1.88M
Goodwill$49.7K$49.7K$49.7K$49.7K$49.7K
Intangible assets$7.52M$7.71M$7.63M$657.2K$443.5K
Total assets$65.5M$54.3M$66.0M$68.0M$49.4M
Total current liabilities$38.3M$25.8M$24.3M$21.7M$29.9M
Long-term debt$3.78M$4.11M$4.61M$5.02M$477.6K
Total liabilities$47.1M$29.8M$30.0M$28.4M$45.0M
Shareholders' equity$18.4M$24.5M$36.0M$39.3M$4.38M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Cosmos Health Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K/A
Reported–––––
Operating cash flow-$8.45M-$7.72M-$15.6M-$14.9M-$7.10M
Capital expenditures$55.7K$418.1K$1.31M$74.2K$581.4K
Free cash flow-$8.50M-$8.14M-$16.9M-$14.9M-$7.68M
Depreciation and amortization$1.36M$1.25M$614.4K$103.2K$449.7K
Stock-based compensation$2.31M$1.69M$577.9K$24.4K–
Share buybacks–$0$100.5K–$376.9K
Investing cash flow-$2.01M-$798.3K-$13.8M-$21.5K-$826.8K
Financing cash flow$14.1M$5.05M$12.7M$35.0M$7.27M
Net change in cash$3.14M-$3.52M-$16.9M$20.5M-$341.9K
Ratio
Stock-based compensation, % of revenue3.5%3.1%1.1%0.0%–

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Cosmos Health Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Aug 18, 2026100.6M+233.1%SEC
May 18, 202654.4M+89.3%SEC
Apr 14, 202650.8M+86.3%SEC
Nov 14, 202534.9M+49.6%SEC
Aug 14, 202530.2M+69.4%SEC
May 15, 202528.8M–SEC
Apr 15, 202527.3M–SEC
Nov 14, 202423.3M+74.2%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.